PI3K inhibitor and CQ could have a synergic role with other types of anti-cancer treatment, such as cisplatin, which reduces the chemoresistance of gastric cancer lines [83], andin case of its combination with oxaliplatin, they have enhanced anti-growth action for gastric cancer cells. This evidence concerns the gene PIK3CA and gastric cancer.